UK seeks input on guidance on non-CE-marked devices for use in flu pandemic
This article was originally published in RAJ Devices
The UK Medicines and Healthcare products Regulatory Agency is asking stakeholders for details of specific issues they would like to be included in guidance the agency is developing on the use of non-CE-marked medical devices during an influenza pandemic1. Responses are due by 20 March.
You may also be interested in...
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib